Keywords: Alzheimer's Disease, CEST & MT, Alzheimer's Disease
Motivation: Alzheimer's disease(AD) presents a major public health and economic challenge, necessitating reliable early detection of biomarkers such as tau and beta-amyloid protein accumulation.
Goal(s): Our primary aim was to establish a standardized neuro CEST MRI pipeline, integrating established neuroimaging tools with CEST processing, and applying it to differentiating cognitively impaired(CI) from normal control(NC).
Approach: A pilot study included nine CI and three NC individuals imaged with a mDixon CEST MRI and processed with a proposed pipeline.
Results: The pipeline effectively reduced erroneous signals in CEST maps and identified significant regional differences between CI and NC(p<0.05).
Impact: The successful implementation of CEST-MRI in AD patients could lead to more timely interventions, guide therapeutic strategies, improve patient outcomes, and decrease the overall cost.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords